In both xenograft and syngeneic murine models, the investigators remarkably found that 2G8 treatment resulted in aggressive tumor growth and tumor regression in TGFβR2 wild‐type and TGFβR2 mutant tumors, respectively. The gene discussed is TGFBR2; the disease is neoplasm.